Medicure Inc (MPH) - Total Assets
Based on the latest financial reports, Medicure Inc (MPH) holds total assets worth CA$26.72 Million CAD (≈ $19.33 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Medicure Inc book value and equity for net asset value and shareholders' equity analysis.
Medicure Inc - Total Assets Trend (2000–2024)
This chart illustrates how Medicure Inc's total assets have evolved over time, based on quarterly financial data.
Medicure Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Medicure Inc's total assets of CA$26.72 Million consist of 53.6% current assets and 46.4% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 24.2% |
| Accounts Receivable | CA$5.26 Million | 17.7% |
| Inventory | CA$3.28 Million | 11.1% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$9.35 Million | 31.5% |
| Goodwill | CA$3.38 Million | 11.4% |
Asset Composition Trend (2000–2024)
This chart illustrates how Medicure Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Medicure Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medicure Inc's current assets represent 53.6% of total assets in 2024, a decrease from 91.5% in 2000.
- Cash Position: Cash and equivalents constituted 24.2% of total assets in 2024, down from 85.4% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 42.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is intangible assets at 31.5% of total assets.
Medicure Inc Competitors by Total Assets
Key competitors of Medicure Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
Medicure Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.44 | 2.03 | 1.27 |
| Quick Ratio | 1.00 | 1.64 | 0.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$3.90 Million | CA$8.19 Million | CA$3.37 Million |
Medicure Inc - Advanced Valuation Insights
This section examines the relationship between Medicure Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.68 |
| Latest Market Cap to Assets Ratio | 0.27 |
| Asset Growth Rate (YoY) | 5.8% |
| Total Assets | CA$29.68 Million |
| Market Capitalization | $7.93 Million USD |
Valuation Analysis
Below Book Valuation: The market values Medicure Inc's assets below their book value (0.27x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Medicure Inc's assets grew by 5.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Medicure Inc (2000–2024)
The table below shows the annual total assets of Medicure Inc from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$29.68 Million ≈ $21.47 Million |
+5.77% |
| 2023-12-31 | CA$28.06 Million ≈ $20.30 Million |
-6.15% |
| 2022-12-31 | CA$29.90 Million ≈ $21.63 Million |
+5.25% |
| 2021-12-31 | CA$28.41 Million ≈ $20.55 Million |
-16.58% |
| 2020-12-31 | CA$34.05 Million ≈ $24.63 Million |
-19.46% |
| 2019-12-31 | CA$42.28 Million ≈ $30.59 Million |
-59.25% |
| 2018-12-31 | CA$103.76 Million ≈ $75.06 Million |
-19.52% |
| 2017-12-31 | CA$128.93 Million ≈ $93.27 Million |
-39.96% |
| 2016-12-31 | CA$214.73 Million ≈ $155.33 Million |
+910.15% |
| 2015-12-31 | CA$21.26 Million ≈ $15.38 Million |
+224.01% |
| 2014-12-31 | CA$6.56 Million ≈ $4.75 Million |
+81.85% |
| 2013-12-31 | CA$3.61 Million ≈ $2.61 Million |
+5.37% |
| 2012-12-31 | CA$3.42 Million ≈ $2.48 Million |
-27.82% |
| 2011-12-31 | CA$4.74 Million ≈ $3.43 Million |
-8.32% |
| 2010-12-31 | CA$5.17 Million ≈ $3.74 Million |
-13.38% |
| 2009-12-31 | CA$5.97 Million ≈ $4.32 Million |
-37.45% |
| 2008-12-31 | CA$9.55 Million ≈ $6.91 Million |
-72.56% |
| 2007-12-31 | CA$34.81 Million ≈ $25.18 Million |
-41.78% |
| 2006-12-31 | CA$59.79 Million ≈ $43.25 Million |
+54.03% |
| 2005-12-31 | CA$38.81 Million ≈ $28.08 Million |
+285.33% |
| 2004-12-31 | CA$10.07 Million ≈ $7.29 Million |
-55.00% |
| 2003-12-31 | CA$22.39 Million ≈ $16.19 Million |
+322.69% |
| 2002-12-31 | CA$5.30 Million ≈ $3.83 Million |
-43.52% |
| 2001-12-31 | CA$9.38 Million ≈ $6.78 Million |
+112.05% |
| 2000-12-31 | CA$4.42 Million ≈ $3.20 Million |
-- |
About Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary … Read more